Skip to main content
Donate
Login
IASLC's 50th Anniversary
IASLC's 50th Anniversary
History
Support The Mission
Support The Mission
Partners for Thoracic Cancer Care
Legacy Society
IASLC Global Member Survey on Inclusivity
About Us
About Us
Strategic Plan
Board of Directors
Committees
Awards
Staff
Careers
Contact
Search
Donate
Login
Conferences & Webinars
Conferences & Webinars
Upcoming Conferences & Webinars
Past Conferences & Webinars
WCLC 2024
Research & Education
Research & Education
Publications, Resources & Guidelines
Journals
Journals
Journal of Thoracic Oncology
JTO Clinical and Research Reports (JTO CRR)
IASLC Reviewer Workshop
Lung Cancer 360
Research Projects
Research Projects
Staging Project
IASLC Global Survey on Biomarker Testing in Lung Cancer 2024 Update
IASLC Neoadjuvant Therapy in Lung Cancers Initiatives
IASLC Atlas of Molecular Testing for Targeted Therapy in Lung Cancer
ELIC
Early-Career Opportunities
News
News
ILCN
Press Releases
Lung Cancer Considered Podcast
Membership
Membership
Become a Member
Renew Your Membership
Partner Society Membership Offers
Patient Advocacy
Patient Advocacy
STARS
Advocacy Partner Spotlight
Lung Cancer Awareness Month 2023 Highlights
Foundation
Foundation
Donor Recognition
Research Grant Program
Grant Recipient Spotlights
Research Grant Recipients
Search
Fulltext search
Fulltext search
Search
Displaying 25 - 36 items out of 267 results
ILCN article
Increasing Understanding about the Role Biosimilar Agents Play in Everyday Practice: A Q&A with Dr. Gary Lyman (Part 2 of 2)
ILCN article
Ensuring Quality of Life During Lung Cancer Survivorship Requires a Multidisciplinary Team
ILCN article
COVID-19 and Lung Cancer: A Call for Immediate Action
ILCN article
A Clinical Trial of PD-L1 Inhibitor Durvalumab and PARP Inhibitor Olaparib for Patients With EGFR-Mutated Transformed SCLC
ILCN article
Large LDCT Lung Cancer Screening Program Suggests Screening Benefits Far Outweigh the Risks
ILCN article
Possible Benefits of Metformin for Lung Cancer Still Unknown
ILCN article
Tyrosine kinase inhibitors (TKI) or monoclonal antibodies (mAb) for the Treatment of NRG1 and, Potentially, NRG2 Fusion–Positive Malignancies
ILCN article
Vemurafenib Alone and Combination for Lung Cancer: A Conversation with Marcelo V. Negrao, MD
ILCN article
Premonitions About Lung Cancer for the Next Decade
ILCN article
Pyrotinib: A Potential New Anti-HER2 Therapy for Lung Cancer
ILCN article
Revised U.S. Food and Drug Administration Trial Eligibility Guidance: A Major Step Toward Transforming Lung Cancer Clinical Trials
ILCN article
Liquid Biopsy: The Key Weapon for Real-Time Monitoring of Patients With NSCLC
Pagination
First
First page
‹
Previous page
1
2
3
4
5
6
7
8
9
…
›
Next page
Last
Last page